Current status and progress of the development of prostate cancer vaccines

At present, common treatments of prostate cancer mainly include surgery, radiotherapy, chemotherapy and hormone therapy. However, patients have high recurrence rate after treatment, and are prone to castration-resistant prostate cancer. Tumor vaccine is based on tumor specific antigen (TSA) and tumor associated antigen (TAA) to activate specific immune response of the body to cancer cells. With continuous maturity of tumor vaccine technology, different forms of prostate cancer vaccines have been developed, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines. In this review, we summarize current status and progress in the development of prostate cancer vaccines.

Automated summary

Currently, common treatments for prostate cancer include surgery, radiation therapy, chemotherapy, and hormone therapy. However, patients often experience high recurrence rates and may develop castration-resistant prostate cancer. Tumor vaccines, which utilize tumor-specific antigens (TSA) and tumor-associated antigens (TAA), aim to activate a specific immune response against cancer cells in the body. Different types of prostate cancer vaccines, such as cellular vaccines, extracellular-based anti-tumor vaccines, polypeptide vaccines, and nucleic acid vaccines, have been developed with the advancement of tumor vaccine technology. This review provides a summary of the current status and progress in the development of prostate cancer vaccines.